Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure

Journal of Medical Microbiology

Volumn 65, Issue 2, 2016, Pages 195-199

  Lorenz, Michael A ^a,b   Moenster, Ryan P ^a,b   Linneman, Travis W ^a,b  

^a VA St Louis Healthcare System   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CREATININE; LOOP DIURETIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC FOOT; DRUG CONTROL; DRUG EFFECT; DRUG USE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY;

ACUTE KIDNEY INJURY; AGED; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES;

EID: 84959288189     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000211     Document Type: Article

References (7)

1. Burgess, L. D. & Drew, R. H. (2014). Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34, 670–676.
2. Davies, S. W., Efird, J. T., Guidry, C. A., Dietch, Z. C., Willis, R. N., Shah, P. M. & Sawyer, R. G. (2015). Top guns: the ‘‘maverick’’ and ‘‘goose’’ of empiric therapy. Surg Infect (Larchmt) 16, 1–10.
3. Dellit, T. H., Owens, R. C., McGowan, J. E., Jr., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O. & other authors (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44, 159–177.
4. Dunn, K., O’Reilly, A., Silke, B., Rogers, T. & Bergin, C. (2011). Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm 33, 208–214.
5. Gomes, D. M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B. J., Kraemer, D. F. & Jankowski, C. A. (2014). Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 34, 662–669.
6. Moenster, R. P., Linneman, T. W., Finnegan, P. M., Hand, S., Thomas, Z. & McDonald, J. R. (2014). Acute renal failure associated with vancomycin and b-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 20, O384–O389.
7. Yam, P., Fales, D., Jemison, J., Gillum, M. & Bernstein, M. (2012). Implementation of an antimicrobial stewardship program in a rural hospital. Am J Health Syst Pharm 69, 1142–1148.